Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Glantz

Showing results (11-20 of 73) with videos related to

Pageof 8
Sort By:
Neurology|February 25, 2011
Is brain the new bone marrow? Stem cells, cancer, and cognition: a working hypothesisNimish A Mohile, Christina M Zoccoli, Michael Glantz
Neurology|August 12, 2021
VEGF and Immune Checkpoint Inhibition for Prevention of Brain Metastases: Systematic Review and Meta-analysisAlireza Mansouri, Varun Padmanaban, Dawit Aregawi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2005
Regarding "abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial"Marc C Chamberlain, Lawrence D Recht, Michael Glantz
Nature Clinical Practice. Oncology|October 22, 2008
New challenges and opportunities in the management of brain metastases in patients with ErbB2-positive metastatic breast cancerMichelle E Melisko, Michael Glantz, Hope S Rugo
World Neurosurgery|October 17, 2025
Prophylactic Intraventricular Vancomycin: A Potential Paradigm Shift in Ommaya Reservoir-Associated Infection PreventionLucas Pari Mitre, Leonardo de Macedo Filho, Michael Glantz
Journal of Neuro-Oncology|November 1, 2015
Impact of provider level, training and gender on the utilization of palliative care and hospice in neuro-oncology: a North-American surveyTobias Walbert, Michael Glantz, Lonni Schultz, et al.
Seminars in Oncology|August 8, 2009
Should intra-cerebrospinal fluid prophylaxis be part of initial therapy for patients with non-Hodgkin lymphoma: what we know, and how we can find out moreUlrich Herrlinger, Michael Glantz, Uwe Schlegel, et al.
The Journal of the American Osteopathic Association|January 24, 2007
Adverse drug reaction to methotrexate: pharmacogenetic originPeter R Przekop, Henry Tulgan, Allison A Przekop, et al.
Seminars in Oncology|August 8, 2009
Understanding the origins of gliomas and developing novel therapies: cerebrospinal fluid and subventricular zone interplayMichael Glantz, Santosh Kesari, Lawrence Recht, et al.
Seminars in Oncology|August 8, 2009
Diagnostic tools for neoplastic meningitis: detecting disease, identifying patient risk, and determining benefit of treatmentMarc C Chamberlain, Michael Glantz, Morris D Groves, et al.
Pageof 8

Showing results (11-20 of 73) with videos related to

Sort By:
Pageof 8
Neurology|February 25, 2011
Is brain the new bone marrow? Stem cells, cancer, and cognition: a working hypothesisNimish A Mohile, Christina M Zoccoli, Michael Glantz
Neurology|August 12, 2021
VEGF and Immune Checkpoint Inhibition for Prevention of Brain Metastases: Systematic Review and Meta-analysisAlireza Mansouri, Varun Padmanaban, Dawit Aregawi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2005
Regarding "abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial"Marc C Chamberlain, Lawrence D Recht, Michael Glantz
Nature Clinical Practice. Oncology|October 22, 2008
New challenges and opportunities in the management of brain metastases in patients with ErbB2-positive metastatic breast cancerMichelle E Melisko, Michael Glantz, Hope S Rugo
World Neurosurgery|October 17, 2025
Prophylactic Intraventricular Vancomycin: A Potential Paradigm Shift in Ommaya Reservoir-Associated Infection PreventionLucas Pari Mitre, Leonardo de Macedo Filho, Michael Glantz
Journal of Neuro-Oncology|November 1, 2015
Impact of provider level, training and gender on the utilization of palliative care and hospice in neuro-oncology: a North-American surveyTobias Walbert, Michael Glantz, Lonni Schultz, et al.
Seminars in Oncology|August 8, 2009
Should intra-cerebrospinal fluid prophylaxis be part of initial therapy for patients with non-Hodgkin lymphoma: what we know, and how we can find out moreUlrich Herrlinger, Michael Glantz, Uwe Schlegel, et al.
The Journal of the American Osteopathic Association|January 24, 2007
Adverse drug reaction to methotrexate: pharmacogenetic originPeter R Przekop, Henry Tulgan, Allison A Przekop, et al.
Seminars in Oncology|August 8, 2009
Understanding the origins of gliomas and developing novel therapies: cerebrospinal fluid and subventricular zone interplayMichael Glantz, Santosh Kesari, Lawrence Recht, et al.
Seminars in Oncology|August 8, 2009
Diagnostic tools for neoplastic meningitis: detecting disease, identifying patient risk, and determining benefit of treatmentMarc C Chamberlain, Michael Glantz, Morris D Groves, et al.
Pageof 8